Compare HII & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HII | BMRN |
|---|---|---|
| Founded | 1886 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 10.0B |
| IPO Year | N/A | 1999 |
| Metric | HII | BMRN |
|---|---|---|
| Price | $335.73 | $61.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $329.83 | $88.42 |
| AVG Volume (30 Days) | 426.1K | ★ 3.8M |
| Earning Date | 02-05-2026 | 10-27-2025 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ 59.53 |
| EPS | ★ 14.50 | 2.68 |
| Revenue | ★ $12,012,000,000.00 | $3,094,001,000.00 |
| Revenue This Year | $5.67 | $13.39 |
| Revenue Next Year | $5.24 | $7.57 |
| P/E Ratio | $23.22 | ★ $22.81 |
| Revenue Growth | 2.60 | ★ 12.39 |
| 52 Week Low | $158.88 | $50.76 |
| 52 Week High | $337.44 | $73.51 |
| Indicator | HII | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 64.74 | 74.25 |
| Support Level | $318.62 | $51.50 |
| Resistance Level | $333.31 | $53.57 |
| Average True Range (ATR) | 9.29 | 1.77 |
| MACD | 1.03 | 0.36 |
| Stochastic Oscillator | 95.39 | 81.60 |
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.